Clinical trial

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

NCT01357655

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2011-09-01

PhasePHASE2

Study timeline

Study start (unknown)2011-09-01Date precision: month

Registry last updated2017-03-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Leukemiaunresolved

Interventions

DasatinibDRUG · verified · RxNorm: dasatinib

BMS-833923DRUG

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Mapped research locations

MadridSpain2 NashvilleTennessee, United States1 ParisFrance1 Salt Lake CityUtah, United States1 ToulouseFrance1 StrasbourgFrance1 EdmontonAlberta, Canada1 LilleFrance1 BordeauxFrance1 KrakowPoland1 LodzPoland1 GdanskPoland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01357655 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.